RxDoctor Payments Data

Heidi Schneider

Family · Chardon, OHNPI 1699489351

Payments from drug & device makers

$6,393in general payments, 2019–2025

Across 328 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$850
  • Novo Nordisk$660
  • Lilly USA, LLC$649
  • Phathom Pharmaceuticals, Inc.$436
  • Amgen$302
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$6,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,393 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$27,445
Medicare patients
164
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$45,012
MounjaroTirzepatide22$26,420
TrulicityDulaglutide24$22,693
OzempicSemaglutide14$18,395
MyrbetriqMirabegron13$5,730
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$1,970
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,046
Rosuvastatin Calcium87$945
Albuterol Sulfate HfaAlbuterol Sulfate50$855
Doxycycline Hyclate25$701
Bupropion XlBupropion Hcl33$694
Gabapentin35$665
Atorvastatin Calcium79$574
Omeprazole44$508
Metoprolol Succinate49$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$649$49,11346 claims
AstraZenecaFarxiga$850$45,01257 claims
Novo NordiskOzempic$660$18,39514 claims
Astellas Pharma US IncMyrbetriq$111$5,73013 claims
AbbVieSynthroid$1,070$34514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →